Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
TransCode Therapeutics Inc. (RNAZ) had Return on Equity of -69.56% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-4.28M |
|
-- |
|
-- |
|
$4.22M |
|
$-4.22M |
|
$-0.06M |
|
$-4.28M |
|
$-4.28M |
|
$-4.28M |
|
$-4.28M |
|
$-4.28M |
|
$-4.28M |
|
$-4.22M |
|
$-4.21M |
|
0.83M |
|
0.83M |
|
$-5.13 |
|
$-5.13 |
|
| Balance Sheet Financials | |
$8.24M |
|
$0.02M |
|
$0.02M |
|
$8.27M |
|
$1.56M |
|
-- |
|
$0.55M |
|
$2.12M |
|
$6.15M |
|
$6.15M |
|
$6.15M |
|
0.83M |
|
| Cash Flow Statement Financials | |
$-7.29M |
|
-- |
|
$8.85M |
|
$5.81M |
|
$7.37M |
|
$1.56M |
|
$0.29M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.27 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-7.29M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-69.56% |
-69.56% |
|
-51.73% |
|
-69.56% |
|
$7.37 |
|
$-8.75 |
|
$-8.75 |
|